查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1458419

全球 ERCP 市場：依治療、產品、適應症、最終用戶和地區劃分的機會和預測（2017-2031）

ERCP Market Assessment, By Treatment, By Product, By Disease Indication, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 229 Pages | 商品交期: 3-5個工作天內

價格

全球 ERCP 市場規模預計將從 2023 年的 16.5 億美元成長到 2031 年的 29.2 億美元，2024-2031 年預測期間複合年增長率為 7.41%。影響全球 ERCP 市場的因素有很多。其中包括技術進步、培訓設施的建立、內視鏡設備的使用增加、對先進內視鏡可視化的需求增加以及胃腸道和肝臟疾病中心的建立。

持續的技術進步對於 ERCP 技術和設備保持創新和提高診斷和治療能力至關重要。隨著這些市場的發展擴大了治療選擇，同時改善了患者護理和手術結果，全球 ERCP 市場正在不斷增長。需要建立培訓設施，以提高醫護人員執行 ERCP 手術的熟練程度。這些設施提供在職培訓、發展專業知識並維持嚴格的病人安全和福祉準則，這對於確保優質醫療保健至關重要。這些培訓中心正在為全球 ERCP 市場的擴張做出貢獻。

由於內視鏡和可視化系統等內視鏡設備的使用不斷擴大，全球 ERCP 市場預計將快速成長，這對於加強和擴大 ERCP 治療至關重要。這些工具將提高診斷和治療的準確性，改善患者的治療效果，並促進肝臟和胃腸道疾病的管理。對複雜內視鏡視覺化工具的需求不斷增長，提高了 ERCP 手術期間患者診斷和治療的準確性。這種不斷增長的需求正在推動全球 ERCP 市場透過使醫療保健專業人員能夠提供更準確的診斷和客製化治療來改善患者的治療結果，從而提高患者護理的標準並支持擴大。

肝臟和胃腸道疾病專業中心的建立將促進 ERCP 的知識、研究和綜合治療。這些設施是改善患者護理、促進診斷和治療複雜肝臟和胃腸道疾病的團隊合作的中心，並在擴大 ERCP 的全球市場方面發揮關鍵作用。

該報告檢視了全球 ERCP 市場，並提供了市場概況，包括依療法、產品、適應症、最終用戶、地區和參與市場的公司概況劃分的趨勢。

目錄

第一章研究方法論

第二章 專案範圍與定義

第三章執行摘要

第四章 2017-2031 年全球 ERCP 市場展望

  • 市場規模及預測
  • 依治療方法
  • 依產品
  • 依指示
  • 依最終用戶
  • 依地區
  • 依公司劃分的市佔率 (%)，2023 年

第五章 2017-2031 年全球 ERCP 市場展望（依地區）

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第六章 2023 年市場規劃

第七章 宏觀環境與產業結構

  • 供需分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第八章市場動態

第九章 監理架構與創新

第十章 主要與企業狀況

第11章價格分析

第十二章案例研究

第十三章 主要進入者展望

  • Olympus Corporation
  • Hoya Corporation
  • Fujifilm Holdings Corporation
  • Boston Scientific Corporation
  • Johnson & Johnson
  • Medtronic plc
  • Conmed Corporation
  • B. Braun Melsungen AG
  • Karl Storz SE & Co KG
  • Boston Scientific Corporation

第十四章 戰略建議

第十五章 查詢及免責聲明

Product Code: MX11216

The global ERCP market is projected to witness a CAGR of 7.41% during the forecast period 2024-2031, growing from USD 1.65 billion in 2023 to USD 2.92 billion in 2031. Various factors shape the global ERCP market. These include technological advancements, setting up of training facilities, growing use of endoscopy devices, increasing demand for advanced endoscopic visualization, and establishing gastrointestinal and liver disease centers.

For ERCP techniques and equipment to remain innovative and improve diagnostic and therapeutic capabilities, ongoing technological advancements are essential. The global ERCP market is growing because of these developments, which also improve patient care and procedural outcomes while extending therapy options. To improve the proficiency of healthcare personnel in carrying out ERCP procedures, training facilities must be established. These facilities are essential to ensure high-quality care because they provide hands-on training, foster expertise, and maintain strict guidelines for patient safety and well-being. These training centers contribute to the expansion of the global ERCP market.

The global ERCP market is expected to grow at a rapid pace due to the growing use of endoscopy instruments, including endoscopes and visualization systems, which are essential for enhancing and expanding ERCP treatments. These tools improve the precision of diagnosis and treatment, improving patient outcomes and advancing the management of liver and gastrointestinal disorders. The increasing demand for sophisticated endoscopic visualization tools improves patient diagnosis and treatment precision during ERCP procedures. This growing demand improves patient outcomes by enabling healthcare practitioners to provide more accurate diagnoses and customized treatments, which, in turn, raises the standard of patient care and drives the expansion of the global ERCP market.

The creation of specialized centers for liver and gastrointestinal disorders fosters knowledge, investigation, and comprehensive treatment of ERCP. These facilities serve as hubs for improved patient care, promote teamwork in the diagnosis and treatment of complex hepatic and gastrointestinal problems, and play a significant role in the expansion of the global ERCP market.

For example, in February 2024, a cutting-edge center for gastrointestinal and liver disorders was opened by prominent private healthcare services company Burjeel Holdings. The facility offers the most cutting-edge medical procedures available. The pancreas, liver, gallbladder, colon, esophagus, stomach, and small intestine are among the ailments that the center focuses on preventing, diagnosing, and treating.

Technological Advancements

Artificial Intelligence (AI) is one of the key technological developments driving the growth of the global ERCP market. AI systems aim to simulate and enhance human intellect to support ERCP procedures by solving problems and making decisions. AI is revolutionizing healthcare delivery by improving diagnostic precision, treatment accuracy, and overall patient outcomes. This allows healthcare practitioners to give patients more effective and personalized care. This wave of AI-powered advancements keeps changing ERCP procedures and gives medical staff better tools to treat patients as best they can, which is a big step forward for the management of gastrointestinal and liver diseases.

AnX Robotica, a trailblazer in cutting-edge gastrointestinal visualization technology, for example, announced in January 2024 that the FDA had cleared NaviCam ProScan for use. ProScan is the first AI-assisted reading tool created to support small bowel capsule endoscopy reviewers for adult patients whose capsule endoscopy images were taken for suspected small intestine hemorrhage. The FDA approved ProScan through the stringent De Novo Submission Process.

Setting Up Training Facilities

The creation of training centers by public and commercial entities has a significant impact on the growth of the global ERCP market. The goal of this partnership is to enhance the skills of medical professionals in executing ERCP procedures, ensuring that patients receive the best possible care. These initiatives enhance knowledge, research, and comprehensive patient care in the field of managing gastrointestinal and liver diseases through these specialized training spaces. The training facilities are designed to help gastroenterologists become more proficient in basic and advanced GI endoscopy, including endoscopic ultrasound. Through these endeavors, newly developed technologies become more widely available and can be employed effectively to fulfill intended purposes.

For example, Fujifilm India and the Department of Gastroenterology at Yashoda Group of Hospitals in Hyderabad formally partnered in September 2023 to develop a training and research facility. Physicians from the Asia-Pacific region are offered extensive training and observation programs in the training facility.

Growing Use of Endoscopy Devices

The global ERCP market is expanding due to the increasing use of advanced endoscopic technologies with improved performance. Patients eventually gain from these advancements because they increase the precision of diagnosis and therapy. The growing prevalence of cancer, government spending on medical research, and an emphasis on advancing endoscopic methods are all factors contributing to the market's expansion. The field of managing gastrointestinal and liver diseases has been significantly shaped by the advancement and widespread use of sophisticated endoscopic equipment.

For instance, in October 2023, Olympus, a manufacturer of medical technology, unveiled its cutting-edge EVIS X1 endoscopic equipment for gastrointestinal (GI) professionals. During the endoscopic screening, the EVIS X1 endoscopy system's Texture and Colour Enhancement Imaging technology improves image color and texture to make lesions and polyps easier to see.

Increasing Demand for Advanced Endoscopic Visualization

The global ERCP market is expanding due to the rising need for sophisticated endoscopic visualization equipment. The components of the endoscopy visualization system include video processors, displays, printers, insufflators, and a light source. Medical equipment like endoscopy devices is used to diagnose disorders by looking at interior organs. Devices that support the visualization and interpretation of endoscopic images are referred to as endoscopy visualization systems and components. The visualization devices enhance the vision during endoscopy and result in an increased efficiency and outcome of the procedure.

For example, in January 2024, OMNIVISION, a developer of semiconductor solutions, including advanced digital imaging and touch display technology, and EndoQuest Robotics, a medical device company leading the development of novel endoluminal robotic technologies, partnered to integrate OMNIVISION's OCHFA CameraCubeChip into EndoQuest's Flexible Robotic System to address the unmet needs in GI and other endoluminal surgeries.

Established European Market

Europe is a major player in the global ERCP business, with France, Germany, and the United Kingdom at the forefront. Important drivers of market expansion include the aging population in Germany and the high level of healthcare spending in France. The sophisticated healthcare infrastructure in Europe and the calculated efforts of industry participants are driving the market's expansion. The region's adoption of cutting-edge technologies and investments in healthcare professional training has further strengthened this trend, underscoring Europe's important influence on the development of ERCP treatments.

For example, in April 2023, Olympus, a Japanese company that produces items for reprography and optics, launched EndoClot Adhesive (ECA), EndoClot Polysaccharide Hemostatic Spray (PHS), and EndoClot Submucosal Injection Solution (SIS) in Europe. EndoClot Plus, Inc. (EPI) created this cutting-edge portfolio; in December 2022, it extended its distribution contract with Olympus. During endoscopic submucosal dissection or resection during gastrointestinal procedures, the EndoClot portfolio aids hemostasis and lifting.

Future Market Scenario (2024 - 2031F)

In growing economies like China, Brazil, and India, the worldwide ERCP market is expanding significantly. Several variables, such as the growth of sophisticated healthcare infrastructure, increased disposable incomes, and the increasing focus on advanced medical procedures in these areas, are responsible for this expansion.

Personalised medicine is where the ERCP market is going in the future. Personalized medicine in ERCP seeks to improve overall patient care quality and optimize results by customizing therapies for each patient.

The increasing prevalence of telemedicine and remote healthcare services is expected to drive the expansion of the global ERCP market, as the integration of ERCP procedures into these platforms is expected to increase.

The global ERCP market is likely to be impacted in the future by anticipated regulatory changes and improvements in global healthcare policies.

Key Players Landscape and Outlook

Businesses looking to expand their market position through mergers and acquisitions are actively attempting to join the global ERCP market. These calculated actions are intended to strengthen competitive positions, get access to new technology, and grow market share. Companies can pool resources, use synergies, and combine strengths through these collaborations to promote innovation and industry growth. This trend demonstrates a dynamic business climate where companies are actively looking for ways to collaborate, come together, and change to suit the ever-evolving demands of the global ERCP market.

For example, in February 2023, Olympus announced that it would purchase Taewoong Medical, a medical device manufacturer based in Korea that makes stents, for USD 370 million. Taewoong Medical produces medical equipment, such as metallic stents, for the GI. Through the acquisition, Olympus hopes to improve the capabilities of its GI endotherapy portfolio.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global ERCP Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Treatment
    • 4.2.1.Balloon Dilation
    • 4.2.2.Stent Insertion
    • 4.2.3.Sphincterotomy
    • 4.2.4.Stone Removal
    • 4.2.5.Biopsy
  • 4.3.By Product
    • 4.3.1.Endotherapy Devices
      • 4.3.1.1.Balloons
      • 4.3.1.2.Band Ligator
      • 4.3.1.3.Baskets
      • 4.3.1.4.Clips
      • 4.3.1.5.Forceps
      • 4.3.1.6.Guidewires
      • 4.3.1.7.Needles
      • 4.3.1.8.Snares
      • 4.3.1.9.Sphincterotomes
      • 4.3.1.10.Stents
    • 4.3.2.Endoscopes
    • 4.3.3.Visualization Systems
    • 4.3.4.Energy Devices
    • 4.3.5.Others
  • 4.4.By Disease Indication
    • 4.4.1.Pancreatitis
    • 4.4.2.Crohn's Disease
    • 4.4.3.Gastroesophageal Reflux Disease
    • 4.4.4.GI Cancer
    • 4.4.5.Barrett's Esophagus
    • 4.4.6.Peptic Ulcer Disease
    • 4.4.7.Others
  • 4.5.By End-user
    • 4.5.1.Hospitals
    • 4.5.2.Diagnostic Laboratories
    • 4.5.3.Ambulatory Surgical Centers & Clinics
    • 4.5.4.Others
  • 4.6.By Region
    • 4.6.1.North America
    • 4.6.2.Europe
    • 4.6.3.Asia-Pacific
    • 4.6.4.South America
    • 4.6.5.Middle East and Africa
  • 4.7.By Company Market Share (%), 2023

5.Global ERCP Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Treatment
      • 5.1.2.1.Balloon Dilation
      • 5.1.2.2.Stent Insertion
      • 5.1.2.3.Sphincterotomy
      • 5.1.2.4.Stone Removal
      • 5.1.2.5.Biopsy
    • 5.1.3.By Product
      • 5.1.3.1.Endotherapy Devices
      • 5.1.3.1.1.Balloons
      • 5.1.3.1.2.Band Ligator
      • 5.1.3.1.3.Baskets
      • 5.1.3.1.4.Clips
      • 5.1.3.1.5.Forceps
      • 5.1.3.1.6.Guidewires
      • 5.1.3.1.7.Needles
      • 5.1.3.1.8.Snares
      • 5.1.3.1.9.Sphincterotomes
      • 5.1.3.1.10.Stents
      • 5.1.3.2.Endoscopes
      • 5.1.3.3.Visualization Systems
      • 5.1.3.4.Energy Devices
      • 5.1.3.5.Others
    • 5.1.4.By Disease Indication
      • 5.1.4.1.Pancreatitis
      • 5.1.4.2.Crohn's Disease
      • 5.1.4.3.Gastroesophageal Reflux Disease
      • 5.1.4.4.GI Cancer
      • 5.1.4.5.Barrett's Esophagus
      • 5.1.4.6.Peptic Ulcer Disease
      • 5.1.4.7.Others
    • 5.1.5.By End-user
      • 5.1.5.1.Hospitals
      • 5.1.5.2.Diagnostic Laboratories
      • 5.1.5.3.Ambulatory Surgical Centers & Clinics
      • 5.1.5.4.Others
    • 5.1.6.United States*
      • 5.1.6.1.Market Size & Forecast
      • 5.1.6.1.1.By Value
      • 5.1.6.1.2.By Volume
      • 5.1.6.2.By Treatment
      • 5.1.6.2.1.Balloon Dilation
      • 5.1.6.2.2.Stent Insertion
      • 5.1.6.2.3.Sphincterotomy
      • 5.1.6.2.4.Stone Removal
      • 5.1.6.2.5.Biopsy
      • 5.1.6.3.By Product
      • 5.1.6.3.1.Endotherapy Devices
      • 5.1.6.3.1.1.Balloons
      • 5.1.6.3.1.2.Band Ligator
      • 5.1.6.3.1.3.Baskets
      • 5.1.6.3.1.4.Clips
      • 5.1.6.3.1.5.Forceps
      • 5.1.6.3.1.6.Guidewires
      • 5.1.6.3.1.7.Needles
      • 5.1.6.3.1.8.Snares
      • 5.1.6.3.1.9.Sphincterotomes
      • 5.1.6.3.1.10.Stents
      • 5.1.6.3.2.Endoscopes
      • 5.1.6.3.3.Visualization Systems
      • 5.1.6.3.4.Energy Devices
      • 5.1.6.3.5.Others
      • 5.1.6.4.By Disease Indication
      • 5.1.6.4.1.Pancreatitis
      • 5.1.6.4.2.Crohn's Disease
      • 5.1.6.4.3.Gastroesophageal Reflux Disease
      • 5.1.6.4.4.GI Cancer
      • 5.1.6.4.5.Barrett's Esophagus
      • 5.1.6.4.6.Peptic Ulcer Disease
      • 5.1.6.4.7.Others
      • 5.1.6.5.By End-user
      • 5.1.6.5.1.Hospitals
      • 5.1.6.5.2.Diagnostic Laboratories
      • 5.1.6.5.3.Ambulatory Surgical Centers & Clinics
      • 5.1.6.5.4.Others
    • 5.1.7.Canada
    • 5.1.8.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Treatment
  • 6.2.By Product
  • 6.3.By Disease Indication
  • 6.4.By End-user
  • 6.5.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Regulatory Approvals
  • 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.Olympus Corporation
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Hoya Corporation
  • 13.3.Fujifilm Holdings Corporation
  • 13.4.Boston Scientific Corporation
  • 13.5.Johnson & Johnson
  • 13.6.Medtronic plc
  • 13.7.Conmed Corporation
  • 13.8.B. Braun Melsungen AG
  • 13.9.Karl Storz SE & Co KG
  • 13.10.Boston Scientific Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 2.Global ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 3.Global ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 4.Global ERCP Market Share (%), By Product, 2017-2031F
  • Figure 5.Global ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 6.Global ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 7.Global ERCP Market Share (%), By Region, 2017-2031F
  • Figure 8.North America ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 9.North America ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 10.North America ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 11.North America ERCP Market Share (%), By Product, 2017-2031F
  • Figure 12.North America ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 13.North America ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 14.North America ERCP Market Share (%), By Country, 2017-2031F
  • Figure 15.United States ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 16.United States ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 17.United States ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 18.United States ERCP Market Share (%), By Product, 2017-2031F
  • Figure 19.United States ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 20.United States ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 21.Canada ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 22.Canada ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 23.Canada ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 24.Canada ERCP Market Share (%), By Product, 2017-2031F
  • Figure 25.Canada ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 26.Canada ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 27.Mexico ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 28.Mexico ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 29.Mexico ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 30.Mexico ERCP Market Share (%), By Product, 2017-2031F
  • Figure 31.Mexico ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 32.Mexico ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 34.Europe ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 35.Europe ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 36.Europe ERCP Market Share (%), By Product, 2017-2031F
  • Figure 37.Europe ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 38.Europe ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 39.Europe ERCP Market Share (%), By Country, 2017-2031F
  • Figure 40.Germany ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 41.Germany ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 42.Germany ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 43.Germany ERCP Market Share (%), By Product, 2017-2031F
  • Figure 44.Germany ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 45.Germany ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 46.France ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 47.France ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 48.France ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 49.France ERCP Market Share (%), By Product, 2017-2031F
  • Figure 50.France ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 51.France ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 52.Italy ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 53.Italy ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 54.Italy ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 55.Italy ERCP Market Share (%), By Product, 2017-2031F
  • Figure 56.Italy ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 57.Italy ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 58.United Kingdom ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 59.United Kingdom ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 60.United Kingdom ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 61.United Kingdom ERCP Market Share (%), By Product, 2017-2031F
  • Figure 62.United Kingdom ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 63.United Kingdom ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 64.Russia ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 65.Russia ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 66.Russia ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 67.Russia ERCP Market Share (%), By Product, 2017-2031F
  • Figure 68.Russia ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 69.Russia ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 70.Netherlands ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 71.Netherlands ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 72.Netherlands ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 73.Netherlands ERCP Market Share (%), By Product, 2017-2031F
  • Figure 74.Netherlands ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 75.Netherlands ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 76.Spain ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 77.Spain ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 78.Spain ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 79.Spain ERCP Market Share (%), By Product, 2017-2031F
  • Figure 80.Spain ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 81.Spain ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 82.Turkey ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 83.Turkey ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 84.Turkey ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 85.Turkey ERCP Market Share (%), By Product, 2017-2031F
  • Figure 86.Turkey ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 87.Turkey ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 88.Poland ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 89.Poland ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 90.Poland ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 91.Poland ERCP Market Share (%), By Product, 2017-2031F
  • Figure 92.Poland ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 93.Poland ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 94.South America ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 95.South America ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 96.South America ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 97.South America ERCP Market Share (%), By Product, 2017-2031F
  • Figure 98.South America ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 99.South America ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 100.South America ERCP Market Share (%), By Country, 2017-2031F
  • Figure 101.Brazil ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 102.Brazil ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 103.Brazil ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 104.Brazil ERCP Market Share (%), By Product, 2017-2031F
  • Figure 105.Brazil ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 106.Brazil ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 107.Argentina ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 108.Argentina ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 109.Argentina ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 110.Argentina ERCP Market Share (%), By Product, 2017-2031F
  • Figure 111.Argentina ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 112.Argentina ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 113.Asia-Pacific ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 114.Asia-Pacific ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 115.Asia-Pacific ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 116.Asia-Pacific ERCP Market Share (%), By Product, 2017-2031F
  • Figure 117.Asia-Pacific ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 118.Asia-Pacific ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 119.Asia-Pacific ERCP Market Share (%), By Country, 2017-2031F
  • Figure 120.India ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 121.India ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 122.India ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 123.India ERCP Market Share (%), By Product, 2017-2031F
  • Figure 124.India ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 125.India ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 126.China ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 127.China ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 128.China ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 129.China ERCP Market Share (%), By Product, 2017-2031F
  • Figure 130.China ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 131.China ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 132.Japan ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 133.Japan ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 134.Japan ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 135.Japan ERCP Market Share (%), By Product, 2017-2031F
  • Figure 136.Japan ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 137.Japan ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 138.Australia ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 139.Australia ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 140.Australia ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 141.Australia ERCP Market Share (%), By Product, 2017-2031F
  • Figure 142.Australia ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 143.Australia ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 144.Vietnam ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 145.Vietnam ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 146.Vietnam ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 147.Vietnam ERCP Market Share (%), By Product, 2017-2031F
  • Figure 148.Vietnam ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 149.Vietnam ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 150.South Korea ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 151.South Korea ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 152.South Korea ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 153.South Korea ERCP Market Share (%), By Product, 2017-2031F
  • Figure 154.South Korea ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 155.South Korea ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 156.Indonesia ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 157.Indonesia ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 158.Indonesia ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 159.Indonesia ERCP Market Share (%), By Product, 2017-2031F
  • Figure 160.Indonesia ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 161.Indonesia ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 162.Philippines ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 163.Philippines ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 164.Philippines ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 165.Philippines ERCP Market Share (%), By Product, 2017-2031F
  • Figure 166.Philippines ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 167.Philippines ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 168.Middle East & Africa ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 169.Middle East & Africa ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 170.Middle East & Africa ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 171.Middle East & Africa ERCP Market Share (%), By Product, 2017-2031F
  • Figure 172.Middle East & Africa ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 173.Middle East & Africa ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 174.Middle East & Africa ERCP Market Share (%), By Country, 2017-2031F
  • Figure 175.Saudi Arabia ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 176.Saudi Arabia ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 177.Saudi Arabia ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 178.Saudi Arabia ERCP Market Share (%), By Product, 2017-2031F
  • Figure 179.Saudi Arabia ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 180.Saudi Arabia ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 181.UAE ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 182.UAE ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 183.UAE ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 184.UAE ERCP Market Share (%), By Product, 2017-2031F
  • Figure 185.UAE ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 186.UAE ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 187.South Africa ERCP Market, By Value, In USD Billion, 2017-2031F
  • Figure 188.South Africa ERCP Market, By Volume, In Million Units, 2017-2031F
  • Figure 189.South Africa ERCP Market Share (%), By Treatment, 2017-2031F
  • Figure 190.South Africa ERCP Market Share (%), By Product, 2017-2031F
  • Figure 191.South Africa ERCP Market Share (%), By Disease Indication, 2017-2031F
  • Figure 192.South Africa ERCP Market Share (%), By End-user, 2017-2031F
  • Figure 193.By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194.By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195.By Disease Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023